LSBCF (LakeShore Biopharma Co) Intangible Assets: $10.05 Mil (As of Mar. 2025)


What is LakeShore Biopharma Co Intangible Assets?

LakeShore Biopharma Co LSBCF Intangible Assets is $10.05 Mil as of Mar. 2025.

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. LakeShore Biopharma Co's intangible assets for the quarter that ended in Mar. 2025 was $10.05 Mil.

LakeShore Biopharma Co  (OTCPK:LSBCF) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.

Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.

LakeShore Biopharma Co Intangible Assets Related Terms

LakeShore Biopharma Co Intangible Assets Historical Data

* Premium members only.

The historical data trend for LakeShore Biopharma Co's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co Intangible Assets Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Intangible Assets
12.87 12.72 11.33 9.89 10.05

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
Intangible Assets Get a 7-Day Free Trial Premium Member Only 11.33 10.23 9.89 9.63 10.05

LakeShore Biopharma Co Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.

Frequently Asked Questions Learn more about Intangible Assets →
What does a Intangible Assets of $10.05 Mil mean?
LakeShore Biopharma Co (LSBCF) has a Intangible Assets of $10.05 Mil as of Mar. 2025. Intangible assets include patents, goodwill and trade secrets. View historical data on LakeShore Biopharma Co and its competitors.
Is LakeShore Biopharma Co's Intangible Assets too high?
LakeShore Biopharma Co's current Intangible Assets is $10.05 Mil.
How does LakeShore Biopharma Co's Intangible Assets compare to ACUT and PPCB?
LakeShore Biopharma Co's Intangible Assets of $10.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intangible Assets for a Biotechnology company?
A good Intangible Assets depends on the Biotechnology industry context. However, Intangible Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intangible Assets mean?
A high Intangible Assets can signal that a stock is expensive relative to its fundamentals. Intangible assets include patents, goodwill and trade secrets. View historical data on LakeShore Biopharma Co and its competitors. LakeShore Biopharma Co's current Intangible Assets is $10.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current Intangible Assets of $10.05 Mil. The current Intangible Assets is $10.05 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intangible Assets calculated?
Intangible Assets is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current Intangible Assets is $10.05 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LakeShore Biopharma Co Business Description

Address 38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.